Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Moderated by:

Mark Shapiro, Vice President of Clinical Development, Clinipace Worldwide

mark shapiroA pharmacologist by training, Mr. Shapiro has more than 20 years of experience spanning virtually all aspects of drug development.  Mr. Shapiro completed an MBA at Duke University’s Fuqua School of Business.  Prior to that, he did Masters and Doctoral work in pharmacology and biomolecular pharmacology at the Boston University School of Medicine.  He received a Bachelor’s degree in chemistry at Virginia Tech.  In addition, he has received several professional distinctions including Duke University’s Certificate in Health Sector Management and professional certifications in both Regulatory Affairs and Clinical Research from the Regulatory Affairs Professional Society and Association of Clinical Research Professionals.

Presented by:

Peter Langecker, MD, PhD; Executive Medical Director, Global Oncology, Clinipace Worldwide

peter langeckerPeter has over 25 years of extensive hands-on experience in establishing and conducting industry-sponsored oncology and hematology clinical research and development according to GCP, GLP and GMP regulations. His primary responsibilities at Clinipace Worldwide include the provision of internal and external drug development, regulatory strategy and medical affairs consulting to Clinipace project teams and clients. Peter’s medical training and published research is focused on preclinical and clinical oncology and the hormonal regulation of breast cancer. He is an author and co-author of over 50 publications and posters.